Tags : Biosimilars

Insights+

Insights+ Key Biosimilars Events of May 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of May, Samsung initiated patient enrollment in the P-III […]Read More

Biosimilars

Xcenda’s FormularyDecisions Launches Resource Hub for Biosimilars

Shots: FormularyDecisions’ new feature will provide registered users with centralized access to pertinent product and drug pipeline information, regulatory guidance and state-specific substitution laws The biosimilar hub will provide users an interactive chart of the US biosimilar market landscape, curated biosimilar resources and dynamic repository of state substitution laws for biosimilar products With the hub, […]Read More

Biosimilars

NCCN Collaborates with Pfizer for New Biosimilars Research Projects in

Shots: NCCN collaborates with Pfizer to select ten projects to receive funding and strengthen innovations to improve the lives of people with cancer and adopt biosimilars in oncology NCCN committed to exploring new avenues with the availability of affordable, effective treatment options in oncology NCCN ORP will support preclinical, translational, clinical research, and quality improvement […]Read More

Biosimilars

Cipla Expands its Partnership with Alvotech to Commercialize Biosimilars in

Shots: The companies collaborated for marketing and distribution of four biosimilars in Australia and New Zealand Cipla Gulf will be responsible for commercialization of patented biosimilars of the biologic medicine brands, covering therapeutic categories across immunology, osteoporosis, oncology as well as ophthalmology Alvotech will manufacture and develop the products and will be distributed by Cipla […]Read More

Biosimilars

EMA’s CHMP Recommends the Approval of Two Bevacizumab Biosimilars

Shots: The EMA’s CHMP has adopted the positive opinion recommending the approval of two biosimilar bevacizumab medicines, Alymsys and Oyavas for the treatment of carcinoma of the colon or rectum, breast cancer, NSCLC, RCC, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix Mabxience’s Alymsys and STADA’s Oyavas both show comparable […]Read More

Biosimilars

Alvotech and Cipla Collaborate to Ensure Access to Biosimilars in

Shots: Alvotech and Cipla entered an exclusive partnership to provide patients with better access to high quality and cost-effective biosimilar medicines in South Africa Alvotech will be responsible for the development and supply of the products and Cipla will be responsible for the registration and commercialization The biosimilar portfolio will include five biosimilars- two for […]Read More

Insights+

Insights+ Key Biosimilars Events of August 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Mylan with its partner Lupin and Biocon launched Nepexto (biosimilar, etanercept) and Semglee (insulin glargine injection) in Germany & in the US, respectively. Additionally, Formycon and Bioeq planned to initiate P-III MAGELLAN-AMD Trial for its FYB203 (biosimilar, […]Read More